Agile Therapeutics, Inc
AGRX
AGRX: Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
moreShow AGRX Financials
Recent trades of AGRX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AGRX's directors and management
Government lobbying spending instances
-
$45,000 Jul 17, 2023 Issue: Health Issues
-
$45,000 Apr 17, 2023 Issue: Health Issues
-
$45,000 Jan 19, 2023 Issue: Health Issues
-
$45,000 Oct 20, 2022 Issue: Health Issues
-
$45,000 Jul 18, 2022 Issue: Health Issues
-
$45,000 Apr 20, 2022 Issue: Health Issues
-
$60,000 Jan 19, 2022 Issue: Health Issues
-
$50,000 Oct 20, 2021 Issue: Health Issues
-
$50,000 Jul 20, 2021 Issue: Health Issues
-
$20,000 Apr 20, 2021 Issue: Health Issues
New patents grants
-
Patent Title: Transdermal contraceptive hormones delivery Oct. 10, 2017
-
Patent Title: Transdermal contraceptive hormones delivery Oct. 03, 2017
-
Patent Title: Transdermal contraceptive hormones delivery Oct. 03, 2017
-
Patent Title: Transdermal contraceptive hormones delivery Oct. 03, 2017
-
Patent Title: Dermal delivery compositions and methods Jun. 14, 2016
-
Patent Title: Contraceptive transdermal delivery of hormones Dec. 01, 2015
-
Patent Title: Contraceptive transdermal delivery of hormones Dec. 01, 2015
-
Patent Title: Contraceptive transdermal delivery of hormones Dec. 01, 2015
-
Patent Title: Contraceptive transdermal delivery of hormones Nov. 24, 2015
-
Patent Title: Dermal delivery device Jun. 09, 2015
-
Patent Title: Transdermal hormone delivery system: compositions and methods Nov. 11, 2014
-
Patent Title: Dermal delivery device with in situ seal Jun. 10, 2014
-
Patent Title: Dermal delivery device with reduced loss of its volatile components Aug. 21, 2012
-
Patent Title: Transdermal hormone delivery system: compositions and methods Jul. 17, 2012
-
Patent Title: Transdermal hormone delivery system: compositions and methods Jul. 17, 2012
Federal grants, loans, and purchases
Followers on AGRX's company Twitter account
Number of mentions of AGRX in WallStreetBets Daily Discussion
Recent insights relating to AGRX
Recent picks made for AGRX stock on CNBC
ETFs with the largest estimated holdings in AGRX
Flights by private jets registered to AGRX